| Title |
Intravenous immunoglobulin for Guillain-Barré syndrome
|
|---|---|
| Published in |
Cochrane database of systematic reviews, September 2014
|
| DOI | 10.1002/14651858.cd002063.pub6 |
| Pubmed ID | |
| Authors |
Richard AC Hughes, Anthony V Swan, Pieter A van Doorn |
| Abstract |
Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007, 2010 and 2012. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective. |
Twitter Demographics
The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 25% |
| Australia | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 570 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | <1% |
| Netherlands | 1 | <1% |
| Norway | 1 | <1% |
| Fiji | 1 | <1% |
| Canada | 1 | <1% |
| Spain | 1 | <1% |
| Peru | 1 | <1% |
| Unknown | 559 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 84 | 15% |
| Student > Master | 77 | 14% |
| Researcher | 65 | 11% |
| Other | 59 | 10% |
| Student > Postgraduate | 58 | 10% |
| Other | 108 | 19% |
| Unknown | 119 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 230 | 40% |
| Nursing and Health Professions | 39 | 7% |
| Neuroscience | 37 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 26 | 5% |
| Agricultural and Biological Sciences | 21 | 4% |
| Other | 72 | 13% |
| Unknown | 145 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 371. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2023.
All research outputs
#80,088
of 24,520,935 outputs
Outputs from Cochrane database of systematic reviews
#143
of 12,933 outputs
Outputs of similar age
#670
of 255,436 outputs
Outputs of similar age from Cochrane database of systematic reviews
#3
of 220 outputs
Altmetric has tracked 24,520,935 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,933 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,436 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 220 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.